Publications by authors named "Nadine Pletsch"

Claim this Profile
O
Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV.
Ulrike Proetel, Nadine Pletsch, Michael Lauseker, Martin C Müller, Benjamin Hanfstein

Ann Hematol· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.
Rüdiger Hehlmann, Martin C Müller, Michael Lauseker, Benjamin Hanfstein, Alice Fabarius, Nadine Pletsch

J Clin Oncol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.
Rüdiger Hehlmann, Michael Lauseker, Susanne Jung-Munkwitz, Armin Leitner, Martin C Müller, Nadine Pletsch

J Clin Oncol· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.
Susanne Saussele, Michael Lauseker, Alois Gratwohl, Dietrich W Beelen, Donald Bunjes, Nadine Pletsch

Blood· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis